| human | Q5 |
| P269 | IdRef ID | 110742478 |
| P213 | ISNI | 0000000359511772 |
| P496 | ORCID iD | 0000-0002-8065-9635 |
| P214 | VIAF ID | 220251499 |
| P184 | doctoral advisor | Thierry Frébourg | Q32424940 |
| P108 | employer | University of California, Irvine | Q868421 |
| P734 | family name | Tougeron | Q119845062 |
| Tougeron | Q119845062 | ||
| Tougeron | Q119845062 | ||
| P735 | given name | David | Q18057751 |
| David | Q18057751 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q97566989 | A diagnostic biopsy-adapted immunoscore predicts response to neoadjuvant treatment and selects patients with rectal cancer eligible for a watch-and-wait strategy |
| Q82443632 | A rare case of mantle cell lymphoma as lymphomatous polyposis with widespread involvement of the digestive tract |
| Q83566624 | ABCB4/MDR3 gene mutations and cholangiocarcinomas |
| Q87481652 | Absence of IDH mutation in colorectal cancers with microsatellite instability |
| Q46728624 | Analysis of factors influencing molecular testing at diagnostic of colorectal cancer |
| Q40608710 | Anti program death-1/anti program death-ligand 1 in digestive cancers |
| Q37626475 | Aspirin and colorectal cancer: back to the future |
| Q50198550 | Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK). |
| Q48010330 | Association between clinicopathological characteristics and RAS mutation in colorectal cancer |
| Q35832569 | Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinoma |
| Q91994664 | BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study |
| Q33793750 | Beclin 1 and UVRAG confer protection from radiation-induced DNA damage and maintain centrosome stability in colorectal cancer cells |
| Q41051631 | Cardiovascular events in chronic hepatitis C: prognostic value of liver stiffness evolution |
| Q43132795 | Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. |
| Q49567980 | Clinical outcome of portal vein thrombosis in patients with digestive cancers: A large AGEO multicenter study. |
| Q37726636 | Colonoscopy uptake for high-risk individuals with a family history of colorectal neoplasia: A multicenter, randomized trial of tailored counseling versus standard information. |
| Q42585933 | Comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer' |
| Q83785926 | Control of pelvic symptoms in patients with rectal cancer and synchronous metastases |
| Q50965911 | Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy. |
| Q44247708 | Definitive chemoradiotherapy in patients with esophageal adenocarcinoma: an alternative to surgery? |
| Q96226180 | Detection of Colorectal Cancer and Advanced Adenoma by Liquid Biopsy (Decalib Study): The ddPCR Challenge |
| Q45376093 | Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. |
| Q40029238 | Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study |
| Q89001806 | Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study |
| Q46050091 | Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. |
| Q42407052 | Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. |
| Q96291112 | Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer |
| Q38685749 | Future perspectives of circulating tumor DNA in colorectal cancer. |
| Q47423452 | Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study |
| Q34658903 | Genetic variations of the A13/A14 repeat located within the EGFR 3' untranslated region have no oncogenic effect in patients with colorectal cancer |
| Q88006769 | Heterogeneity of mismatch repair defect in colorectal cancer and its implications in clinical practice |
| Q41732004 | High plasma levels of the pro-inflammatory cytokine IL-22 and the anti-inflammatory cytokines IL-10 and IL-1ra in acute pancreatitis. |
| Q42855352 | Hyperkeratotic eczema of the nipple and areola associated with sorafenib treatment. |
| Q112572072 | Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective observational cohort study (CAPANCOVID) |
| Q40850728 | Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability |
| Q39130366 | Irreversible Electroporation for Locally Advanced Pancreatic Cancer: Where Do We Stand in 2017? |
| Q54021234 | Irreversible electroporation for locally advanced pancreatic cancer. |
| Q33693309 | KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). |
| Q21133026 | MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells |
| Q37895778 | Management of esophageal adenocarcinoma. |
| Q91999863 | Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR) |
| Q88318909 | Mutation in BRAF V600E: A Poor Prognostic Marker in Stage III Colon Cancers With Deficient MMR? |
| Q33425869 | Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort |
| Q48866055 | Outcome of primary tumor in patients with synchronous stage IV colon or rectal cancer: so much the same yet so different. |
| Q102056673 | Panel gene profiling of small bowel adenocarcinoma, results from the NADEGE prospective cohort |
| Q60960810 | Pathological and Molecular Characteristics of Colorectal Cancer with Brain Metastases |
| Q40583605 | Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. |
| Q50154156 | Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study). |
| Q40202410 | Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort |
| Q46251612 | Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease. |
| Q92076296 | Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations |
| Q87097051 | Predictors of disease-free survival in colorectal cancer with microsatellite instability: An AGEO multicentre study |
| Q51813172 | Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): A French multicentric survey. |
| Q92866507 | Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study |
| Q50041458 | RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study |
| Q36206880 | Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Entérologues Oncologues |
| Q34683929 | Regulatory T lymphocytes are associated with less aggressive histologic features in microsatellite-unstable colorectal cancers. |
| Q81322834 | Response to definitive chemoradiotherapy and survival in patients with an oesophageal adenocarcinoma versus squamous cell carcinoma: a matched-pair analysis |
| Q52689522 | Results and challenges of immune checkpoint inhibitors in colorectal cancer. |
| Q36977519 | Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. |
| Q40860251 | Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues. |
| Q83676605 | Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study |
| Q104143266 | Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX) |
| Q92486023 | Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients |
| Q81600118 | Small-bowel adenocarcinoma in patient with Crohn's disease: report of a series of three cases |
| Q36070573 | Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program |
| Q52340676 | Th-17 response and antimicrobial peptide expression are uniformly expressed in gastric mucosa of Helicobacter pylori-infected patients independently of their clinical outcomes. |
| Q47100522 | Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study. |
| Q34985439 | Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. |
| Q37092577 | Unusual iris metastasis from anal cancer: a case report. |
| Q83938601 | Unusual skeletal muscle metastasis from gastric adenocarcinoma |
| Q81724063 | Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer |
| Q98903998 | Where to Biopsy to Detect Helicobacter pylori and How Many Biopsies Are Needed to Detect Antibiotic Resistance in a Human Stomach |
| Q83177746 | [Gastric tumors] |
| Q86411792 | [Immune response and colorectal cancer] |
| Q45403194 | [Immunotherapy for colorectal cancer]. |
| Q79520487 | [Severe varicella infection during treatment with infliximab for Crohn's disease] |
| Q32424940 | Thierry Frébourg | doctoral student | P185 |
Search more.